Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 18/20 | 0.59 |
| ▸ | BRD4 | O60885 | 2/20 | 0.44 |
| ▸ | PLK3 | Q9H4B4 | 9/20 | 0.43 |
| ▸ | PLK2 | Q9NYY3 | 9/20 | 0.43 |
| ▸ | TAF1 | P21675 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL74771 | 0.86 | PLK1 (0.53) | PLK1BRD4PLK3PLK2TAF1 | |
| SCHEMBL92591 | 0.86 | PLK1 (0.53) | PLK1BRD4PLK3PLK2 | |
| SCHEMBL74216 | 0.81 | PLK1 (0.81) | PLK1BRD4PLK3PLK2TAF1 | |
| SCHEMBL74215 | 0.81 | PLK1 (0.81) | PLK1BRD4PLK3PLK2TAF1 | |
| SCHEMBL73871 | 0.78 | PLK1 (0.91) | PLK1BRD4PLK3PLK2TAF1 | |
| SCHEMBL73872 | 0.78 | PLK1 (0.91) | PLK1BRD4PLK3PLK2TAF1 | |
| SCHEMBL88828 | 0.78 | PLK1 (0.47) | PLK1BRD4PLK3PLK2 | |
| SCHEMBL88829 | 0.78 | PLK1 (0.47) | PLK1BRD4PLK3PLK2 | |
| SCHEMBL384393 | 0.77 | BRD4 (0.68) | PLK1BRD4PLK3PLK2TAF1 | |
| SCHEMBL384394 | 0.77 | BRD4 (0.68) | PLK1BRD4PLK3PLK2TAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122879-A1 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122879-A1 | COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K6, MAP3K1 | PLK1 33/4885BRD4 928/4885PLK3 373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.